Cargando…

Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial

BACKGROUND: In ENSURE-AF study, edoxaban had similar efficacy and safety profile versus enoxaparin–warfarin (enox–warf) in patients undergoing electrical cardioversion of non-valvular atrial fibrillation. OBJECTIVES: To evaluate the efficacy and safety of edoxaban versus enox–warf in patients who we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kozieł, Monika, Al-Saady, Naab, Hjortshøj, Søren P., Goudev, Assen, Huber, Kurt, Cohen, Ariel, Jin, James, Melino, Michael, Winters, Shannon M., Goette, Andreas, Lip, Gregory Y. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7376082/ https://www.ncbi.nlm.nih.gov/pubmed/31915996 http://dx.doi.org/10.1007/s00392-019-01594-9

Ejemplares similares

Clinical factors related to successful or unsuccessful cardioversion in the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE‐AF) randomized trial
por: Lip, Gregory Y. H., et al.
Publicado: (2020)

Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study
por: Goette, Andreas, et al.
Publicado: (2018)

Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin
por: Bavalia, Roisin, et al.
Publicado: (2021)

Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism
por: Vandell, Alexander G, et al.
Publicado: (2017)

Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
por: Krejczy, Martin, et al.
Publicado: (2015)

Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin
por: Bistervels, Ingrid M., et al.
Publicado: (2022)

Deep Vein Thrombosis in Severe Motor and Intellectual Disabilities Patients and Its Treatment by Anticoagulants of Warfarin Versus Edoxaban
por: Ohmori, Hiromitsu, et al.
Publicado: (2019)

Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis
por: Wang, Yapeng, et al.
Publicado: (2023)

Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis
por: Merino, Jose L, et al.
Publicado: (2019)

Cost-effectiveness of edoxaban compared to warfarin for the treatment and secondary prevention of venous thromboembolism in the UK
por: Clay, Emilie, et al.
Publicado: (2018)

Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial
por: Xu, Haiyan, et al.
Publicado: (2016)

Effectiveness and safety of edoxaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies
por: Alsultan, Mohammed M., et al.
Publicado: (2023)

Dabigatran Versus Warfarin for Direct Current Cardioversion in Atrial Fibrillation
por: Benamer, Sufyan, et al.
Publicado: (2016)

Resolution of left ventricular thrombus by edoxaban after failed treatment with warfarin overdose: A case report
por: Kao, Pei-Heng, et al.
Publicado: (2019)

Edoxaban in patients with non-valvular atrial fibrillation after percutaneous coronary intervention: ENCOURAGE-AF design
por: Baldus, Stephan, et al.
Publicado: (2023)

Safety and efficacy of uninterrupted treatment with edoxaban or warfarin during the peri‐procedural period of catheter ablation for atrial fibrillation
por: Naito, Kazuya, et al.
Publicado: (2020)

Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe)
por: De Caterina, Raffaele, et al.
Publicado: (2019)

Editorial to “Safety and Efficacy of Uninterrupted Treatment with Edoxaban or Warfarin During the Peri‐Procedural Period of Catheter Ablation for Atrial Fibrillation”
por: Fukaya, Hidehira
Publicado: (2020)

Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation/warfarin for symptomatic deep vein thrombosis: A multicenter feasibility study
por: Piazza, Gregory, et al.
Publicado: (2016)

Edoxaban in venous thromboembolism and stroke prevention: an appraisal
por: Proietti, Marco, et al.
Publicado: (2016)

The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma
por: Siriez, Romain, et al.
Publicado: (2022)

Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin—A Nationwide Cohort Study
por: Pallisgaard, Jannik Langtved, et al.
Publicado: (2015)

Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT‐AF/VTE)—Trial design
por: Colonna, Paolo, et al.
Publicado: (2018)

Edoxaban use in the context of dental procedures: analysis from the EMIT-AF/VTE database
por: Chen, Cathy, et al.
Publicado: (2023)

Efficacy and safety of NOAC versus warfarin in AF patients with left atrial enlargement
por: Wu, Victor Chien-Chia, et al.
Publicado: (2020)

Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai‐VTE study
por: Scheres, LJJ, et al.
Publicado: (2018)

Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Score–Matched Study
por: Rago, Anna, et al.
Publicado: (2020)

Pleiotropic effects of NOACs with focus on edoxaban: scientific findings and potential clinical implications
por: Goette, Andreas, et al.
Publicado: (2023)

Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF–TIMI 48 Trial
por: Kato, Eri Toda, et al.
Publicado: (2016)

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
por: Hohnloser, Stefan H, et al.
Publicado: (2019)

Efficacy and safety of edoxaban in patients with chronic thromboembolic pulmonary hypertension: protocol for a multicentre, randomised, warfarin-controlled, parallel group trial - KABUKI trial
por: Hosokawa, Kazuya, et al.
Publicado: (2022)

Managing patients taking edoxaban in dentistry
por: Curto, Adrian, et al.
Publicado: (2017)

Edoxaban: Minor bleeding: case report
Publicado: (2022)

Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial
por: Zelniker, Thomas A., et al.
Publicado: (2021)

Corrigendum to: Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
Publicado: (2019)

Predictive Factors and Clinical Events Associated with Edoxaban Interruption and Heparin Bridging Strategy: EMIT-AF/VTE
por: Santamaria, Amparo, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Apixaban Versus Edoxaban in Patients with Atrial Fibrillation for Stroke Prevention
por: Oyagüez, Itziar, et al.
Publicado: (2019)

NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis
por: Hicks, Tim, et al.
Publicado: (2016)

The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease
por: van Ommen, Cornelia Heleen, et al.
Publicado: (2020)

Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism
por: Said, Karim
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2jmcf79l75bcd0erk2mm8dspqb